PEDIATRIC ATORVASTATIN IN DIABETES TRIAL

Posted by Unknown 0 komentar
Download Pediatric Atorvastatin in Diabetes Trial.pdf Fifty-one children with type 1 diabetes mellitus (DM1) participated in a double blinded, randomized, cross-over pilot study to determine whether 12 weeks of daily atorvastatin (20 mg daily) would reduce arterial stiffness and im-prove endothelial function. Secondary analysis demonstrated potential reduction of arterial stiffness following atorvastatin therapy (p = 0.06). Additional long-term prospective studies with larger numbers of patients are needed.

Pediatric Atorvastatin in Diabetes Trial. Type 1 diabetes mellitus (DM1) is a potent risk factor for premature cardiovascular disease (CVD)1. Children with DM1 as young as 10 years have abnormal vessel stiffness and function demon-strable by non-invasive techniques2. Early and aggressive management of CVD risk factors, such as blood pressure and lipidemia, may reduce the long-term risks for CVD in children with DM13. Because long-term data are not yet available, lipid lowering therapy for the prevention of CVD in children with DM1 remains controversial4. We explored whether a short course of atorvastatin could reduce arterial stiffness and improve endo-thelial function in children with DM1. We hypothesized that 12 weeks of atorvastatin administration would improve measures of arterial stiffness and endothelial function, and reduce low-density lipoprotein cholesterol (LDL-C).

here Pediatric Atorvastatin in Diabetes Trial

0 komentar:

Post a Comment